EquitySector - HealthcareVery High Risk
Direct
NAV (27-Mar-25)
Returns (Since Inception)
Fund Size
₹1,469 Cr
Expense Ratio
0.94%
ISIN
INF179KC1HO1
Minimum SIP
₹100
Exit Load
1.00%
Inception Date
04 Oct 2023
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+32.76%
+17.95% (Cat Avg.)
Since Inception
+38.97%
— (Cat Avg.)
Equity | ₹1,431.65 Cr | 97.48% |
Others | ₹13.91 Cr | 0.95% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹176.08 Cr | 11.99% |
Divi's Laboratories Ltd | Equity | ₹130.93 Cr | 8.91% |
Cipla Ltd | Equity | ₹114.62 Cr | 7.80% |
Lupin Ltd | Equity | ₹81.8 Cr | 5.57% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹71.53 Cr | 4.87% |
Torrent Pharmaceuticals Ltd | Equity | ₹54.13 Cr | 3.69% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹53.81 Cr | 3.66% |
Aurobindo Pharma Ltd | Equity | ₹49.03 Cr | 3.34% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹48.15 Cr | 3.28% |
Ipca Laboratories Ltd | Equity | ₹48.07 Cr | 3.27% |
Eris Lifesciences Ltd Registered Shs | Equity | ₹45.14 Cr | 3.07% |
Glenmark Pharmaceuticals Ltd | Equity | ₹43.91 Cr | 2.99% |
Gland Pharma Ltd | Equity | ₹42.61 Cr | 2.90% |
Wockhardt Ltd | Equity | ₹39.67 Cr | 2.70% |
Vijaya Diagnostic Centre Ltd | Equity | ₹39.07 Cr | 2.66% |
Alkem Laboratories Ltd | Equity | ₹38.92 Cr | 2.65% |
Metropolis Healthcare Ltd | Equity | ₹37.36 Cr | 2.54% |
Piramal Pharma Ltd | Equity | ₹33.32 Cr | 2.27% |
Fortis Healthcare Ltd | Equity | ₹32.56 Cr | 2.22% |
Ami Organics Ltd | Equity | ₹29.08 Cr | 1.98% |
Global Health Ltd | Equity | ₹29.04 Cr | 1.98% |
Suven Pharmaceuticals Ltd | Equity | ₹26.48 Cr | 1.80% |
Ajanta Pharma Ltd | Equity | ₹23.93 Cr | 1.63% |
Bajaj Healthcare Limited - Prefential Issue | Preferred Stock | ₹23.12 Cr | 1.57% |
Laxmi Dental Ltd | Equity | ₹21.86 Cr | 1.49% |
Jubilant Pharmova Ltd | Equity | ₹21.64 Cr | 1.47% |
Dr Reddy's Laboratories Ltd | Equity | ₹20.78 Cr | 1.41% |
Pfizer Ltd | Equity | ₹19.98 Cr | 1.36% |
Sai Life Sciences Ltd | Equity | ₹17.55 Cr | 1.20% |
Zydus Lifesciences Ltd | Equity | ₹17.32 Cr | 1.18% |
Medi Assist Healthcare Services Ltd | Equity | ₹16.81 Cr | 1.14% |
Treps - Tri-Party Repo | Cash - Repurchase Agreement | ₹16.63 Cr | 1.13% |
Bajaj Healthcare Ltd | Equity | ₹6.3 Cr | 0.43% |
Net Current Assets | Cash | ₹-2.72 Cr | 0.19% |
Alembic Pharmaceuticals Ltd | Equity | ₹0.19 Cr | 0.01% |
Large Cap Stocks
34.99%
Mid Cap Stocks
26.54%
Small Cap Stocks
34.47%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹1,402.57 Cr | 95.50% |
Basic Materials | ₹29.08 Cr | 1.98% |
Standard Deviation
This fund
--
Cat. avg.
16.58%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.70
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.18
Higher the better
Since October 2023
Since October 2023
ISIN INF179KC1HO1 | Expense Ratio 0.94% | Exit Load 1.00% | Fund Size ₹1,469 Cr | Age 1 year 5 months | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹25.63 Cr | 20.0% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.1% | 1.0% | ₹754.75 Cr | 13.4% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹754.75 Cr | 11.9% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹37.95 Cr | 15.9% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹200.83 Cr | 19.0% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹200.83 Cr | 16.8% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2441.13 Cr | 19.9% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 2.0% | 1.0% | ₹2441.13 Cr | 18.2% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹809.18 Cr | 13.8% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹17.44 Cr | 15.8% |
Total AUM
₹7,38,172 Cr
Address
“HUL House”, 2nd Floor, Mumbai, 400 020
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Direct
NAV (27-Mar-25)
Returns (Since Inception)
Fund Size
₹1,469 Cr
Expense Ratio
0.94%
ISIN
INF179KC1HO1
Minimum SIP
₹100
Exit Load
1.00%
Inception Date
04 Oct 2023
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+32.76%
+17.95% (Cat Avg.)
Since Inception
+38.97%
— (Cat Avg.)
Equity | ₹1,431.65 Cr | 97.48% |
Others | ₹13.91 Cr | 0.95% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹176.08 Cr | 11.99% |
Divi's Laboratories Ltd | Equity | ₹130.93 Cr | 8.91% |
Cipla Ltd | Equity | ₹114.62 Cr | 7.80% |
Lupin Ltd | Equity | ₹81.8 Cr | 5.57% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹71.53 Cr | 4.87% |
Torrent Pharmaceuticals Ltd | Equity | ₹54.13 Cr | 3.69% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹53.81 Cr | 3.66% |
Aurobindo Pharma Ltd | Equity | ₹49.03 Cr | 3.34% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹48.15 Cr | 3.28% |
Ipca Laboratories Ltd | Equity | ₹48.07 Cr | 3.27% |
Eris Lifesciences Ltd Registered Shs | Equity | ₹45.14 Cr | 3.07% |
Glenmark Pharmaceuticals Ltd | Equity | ₹43.91 Cr | 2.99% |
Gland Pharma Ltd | Equity | ₹42.61 Cr | 2.90% |
Wockhardt Ltd | Equity | ₹39.67 Cr | 2.70% |
Vijaya Diagnostic Centre Ltd | Equity | ₹39.07 Cr | 2.66% |
Alkem Laboratories Ltd | Equity | ₹38.92 Cr | 2.65% |
Metropolis Healthcare Ltd | Equity | ₹37.36 Cr | 2.54% |
Piramal Pharma Ltd | Equity | ₹33.32 Cr | 2.27% |
Fortis Healthcare Ltd | Equity | ₹32.56 Cr | 2.22% |
Ami Organics Ltd | Equity | ₹29.08 Cr | 1.98% |
Global Health Ltd | Equity | ₹29.04 Cr | 1.98% |
Suven Pharmaceuticals Ltd | Equity | ₹26.48 Cr | 1.80% |
Ajanta Pharma Ltd | Equity | ₹23.93 Cr | 1.63% |
Bajaj Healthcare Limited - Prefential Issue | Preferred Stock | ₹23.12 Cr | 1.57% |
Laxmi Dental Ltd | Equity | ₹21.86 Cr | 1.49% |
Jubilant Pharmova Ltd | Equity | ₹21.64 Cr | 1.47% |
Dr Reddy's Laboratories Ltd | Equity | ₹20.78 Cr | 1.41% |
Pfizer Ltd | Equity | ₹19.98 Cr | 1.36% |
Sai Life Sciences Ltd | Equity | ₹17.55 Cr | 1.20% |
Zydus Lifesciences Ltd | Equity | ₹17.32 Cr | 1.18% |
Medi Assist Healthcare Services Ltd | Equity | ₹16.81 Cr | 1.14% |
Treps - Tri-Party Repo | Cash - Repurchase Agreement | ₹16.63 Cr | 1.13% |
Bajaj Healthcare Ltd | Equity | ₹6.3 Cr | 0.43% |
Net Current Assets | Cash | ₹-2.72 Cr | 0.19% |
Alembic Pharmaceuticals Ltd | Equity | ₹0.19 Cr | 0.01% |
Large Cap Stocks
34.99%
Mid Cap Stocks
26.54%
Small Cap Stocks
34.47%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹1,402.57 Cr | 95.50% |
Basic Materials | ₹29.08 Cr | 1.98% |
Standard Deviation
This fund
--
Cat. avg.
16.58%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.70
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.18
Higher the better
Since October 2023
Since October 2023
ISIN INF179KC1HO1 | Expense Ratio 0.94% | Exit Load 1.00% | Fund Size ₹1,469 Cr | Age 1 year 5 months | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹25.63 Cr | 20.0% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.1% | 1.0% | ₹754.75 Cr | 13.4% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹754.75 Cr | 11.9% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹37.95 Cr | 15.9% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹200.83 Cr | 19.0% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹200.83 Cr | 16.8% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2441.13 Cr | 19.9% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 2.0% | 1.0% | ₹2441.13 Cr | 18.2% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹809.18 Cr | 13.8% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹17.44 Cr | 15.8% |
Total AUM
₹7,38,172 Cr
Address
“HUL House”, 2nd Floor, Mumbai, 400 020
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments